Fortis Inc. closed 2.6% below its 52-week high of C$64.39, which the company reached on February 14th.

Fortis Inc. closed 2.9% short of its 52-week high of C$64.39, which the company achieved on February 14th.

Raymond James analyst Theo Genzebu raised the firm’s price target on Fortis (FTS) to C$62.50 from C$61 and keeps a Market Perform rating on the ...

CIBC raised the firm’s price target on Fortis (FTS) to C$65 from C$64 and keeps a Neutral rating on the shares.Discover the Best Stocks and ...

Leading companies like Novartis, Merck, and Bristol Myers Squibb are spearheading advancements, redefining patient treatment possibilities. < ...

Copyright 1998 - 2025 Baystreet.ca Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes ...

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...